From Data to Dialogue: How Real-Time Insights Transform Post-Approval Studies

You’ve spent years getting your drug approved. You’ve launched. Now you need Real-World Evidence (RWE) to support label expansions, reimbursement negotiations, and KOL engagement. But there’s a problem: by the time your post-approval study data is published - 24–36 months after launch - you’ve burned through half your patent exclusivity window.

What if you could engage HCPs with real-time insights while the study is still running? What if MSLs could show anonymised, aggregated data tailored to each HCP’s patient population - not in 2028, but today? That’s “From Data to Dialogue”, and it’s already happening at Climedo.

The Post-Approval Paradox

Patent protection in pharma holds for 20 years from filing, but in reality you only get 10–11 years of exclusivity after launch. Much of the window is spent in Phase I–III trials, regulatory review, and reimbursement negotiations. By the time your drug hits the market, the clock is ticking.

Post-approval studies are designed to generate RWE for label expansions, new indications, and HCP engagement - but traditional timelines create a paradox: the data arrives too late to be useful.

• Launch + 6 months: post-approval study starts enrolling
• Launch + 18 months: data collection complete
• Launch + 24–36 months: data cleaned, analysed, published
• Launch + 10–12 years: generics enter the market

Result: you have 6–8 years to leverage RWE before generics arrive - and you spent 2–3 of those years waiting for data.

The Three Challenges of Post-Approval Studies

• The race against time - Sponsors don’t lack valuable data, they lack timely access. The 24–36 month delay between enrolment and publication erodes the commercial window.
• The devil is in the data - The volume of scientific outcomes published each year is overwhelming. Standing out requires not just convincing data but compelling presentation; static slide decks and PDF reports fall short.
• The struggle to engage patients - Post-launch, patients aren’t incentivised by exclusive access (the drug is commercially available). Drop-out rates in observational studies can reach 30–45%, and high drop-out means limited data and delayed results.

Solution 1: Real-Time Insights

Instead of waiting 24+ months for a static report, make clinical data available in interactive dashboards while the study is still underway. MSLs can filter data by subpopulation in real time and show HCPs anonymised, aggregated data relevant to their practice.

Example: an MSL visits an HCP in Berlin who treats 30–40 year-old women with obesity. The MSL opens the Climedo dashboard, filters by age (30–40), gender (female) and location (Berlin), and shows benchmarking data: “Here’s how your patient cohort compares to the overall study population on weight loss and QoL scores.” The conversation shifts from “Should I prescribe this?” to “How do I optimise outcomes?”

Solution 2: Benchmarking & Progression

Climedo’s Benchmarking feature lets HCPs compare an individual patient against the overall study population, and the Progression feature visualises a patient’s trajectory over time - both available in real time, while the study runs.

Benchmarking use case: the treating HCP selects their patient, filters by body weight/BMI, and sees the patient’s position in a histogram relative to the subpopulation, compared for a given visit (e.g. the 9th) so treatment duration is comparable.

Progression use case: the HCP visualises the trajectory of a patient’s blood sugar over multiple site visits, seeing current progress and detecting outliers or changes at an early stage.

Solution 3: Patient Engagement (Patient Cockpit)

In a Climedo survey of 124 patients, over 50% said they would like a “patient cockpit” with an overview of their study progress. Patients who feel engaged are more likely to stay enrolled and give positive testimonials.

• Overview of therapy/study progress (visits completed, upcoming visits)
• Visualisation of their own data (QoL scores, biomarkers) over time
• Comparison to the anonymised study population (optional)
• Study-related information via digital channels

A Note on Regulatory Context

While modern technology is capable of providing interactive data handling, representative data is not available before statistical analysis of the trial’s data. When leveraging data from an ongoing (observational) study, this data must not be considered representative and must not be used to influence an HCP’s decision on whether to prescribe a treatment. The above is descriptive only with respect to the study of interest and merely serves as a basis for discussion.

Conclusion

Post-approval studies don’t have to be a 2–3 year wait for static reports. With real-time insights, benchmarking, and patient engagement, you can start the scientific dialogue today - not in 2028. Your patent window is too short to wait.

Want to see how leading pharma teams leverage real-time insights in post-approval studies? Book a demo.